Navigation Links
PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
Date:10/29/2008

BOSTON, Oct. 29 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, in partnership with Glenmark Pharmaceuticals Ltd, today announced that it has been recognized by the Good Clinical Practice Journal (GCPj) as the winner of its Most Innovative Patient Recruitment Strategy Award. The award recognizes the impressive collaborative efforts of PAREXEL and study sponsor Glenmark, a research-driven innovation-led organization that focuses on delivering new molecules, in taking an innovative approach to accelerating study timelines. This approach substantially helped Glenmark make earlier, more effective decisions about a novel diabetes compound by incorporating a combined protocol design into an early phase clinical development program, which is now progressing well in Phase IIb. The program also leveraged PAREXEL's unique, global early phase patient recruitment strategies.

According to Helena Jensen, Publisher of the Good Clinical Practice Journal, "We are pleased to recognize PAREXEL for its outstanding expertise in volunteer and patient recruitment as well as its novel approaches in early phase development. PAREXEL has demonstrated the kind of innovation that is required in partnering with biopharmaceutical companies to help them address growing study complexity, avoid late stage failures, use rapid recruitment access methods, and bring important, safe and effective treatments to the market."

"Our global clinical pharmacology team worked with Glenmark to develop an innovative way to accelerate recruitment, leverage global strategies, and use regulatory submission timelines to full advantage for the company's clinical development program," said Michelle
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
2. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
3. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
4. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
5. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
7. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
8. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
11. PAREXEL International Announces 2-For-1 Stock Split

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... DNA Genotek, a leading provider of produ...ced that Tepnel Pharmaceutical Services will offer...f its nucleic acid extraction and genotyping servi...December 1, 2009 -- DNA Genotek , a leading provi...today announced that Tepnel Pharmaceutical Servic...
(Date:12/1/2009)... Michael R. Drapp, a 34-year veteran of t...rade; Technologies, a business development and int...he emerging nanotechnology space. The company als...t as a nanotechnology incubator. , ... Michael R. Drapp , a 34-year veteran of the high...
(Date:11/30/2009)... YORK, Nov. 30 The Mich...FF) today announced $1.5 million in total awards t...y disease-modifying therapies for Parkinson,s dise...oaches to Drug Discovery for Parkinson,s Disease ...ation, plc (NYSE: ELN ), a neuroscience-based bi...
(Date:11/30/2009)... CHANGCHUN, China and LOS ANGELES, Nov. 30 /PRNe...icals, Inc. (OTC Bulletin Board: CYXN; ,China Yong...manufacturer, distributor and,retailer of pharmace...has,completed preparation for distribution of medi...hinese government recently formalized the nation,s...
Breaking Biology Technology:Tepnel Pharmaceutical Services to Offer DNA Genotek's Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 2Tepnel Pharmaceutical Services to Offer DNA Genotek's Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 3Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 2Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 3Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 4The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3
...be held on March 13, 2008 at 9:00 am (Eastern) ... Kong), SHANGHAI, China, Feb. 21 /Xinhua-PRNewswi...("WuXi PharmaTech" or "the Company"), the leading,...rch and development,outsourcing company, today ann...sults for the fourth quarter and full year ended D...
...LADELPHIA, February 21, Shire plc (LSE: SHP, NASDA...ompany announces results for the twelve months,to ...ant growth in launched,products., - All $ valu... Q4 2007 - Product sale... to $661m, - New product sales $489m, 23% of prod...
...to Follow, THE WOODLANDS, Texas, Feb. 20 Lexicon...se its fourth quarter and,year end 2007 financial ...cial markets close. Lexicon management will hold a...nt progress, financial results for 2007 and,financ... March 6, 2008., The dial-in number for the confe...
Other Biology Technology:WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008 2Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 2Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 3Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 4Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 5Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 6Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 7Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 8Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 9Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 10Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 11Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 12Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 13Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 14Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 15Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 16Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 17Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 18Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 19Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 20Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 21Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 22Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 23Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 24Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 25Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 26Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 27Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 28Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 29Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 30Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 31Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 32Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 33Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008 2
(Date:11/30/2009)..., VILNIUS, Lithuania, Nov. 30 N... a provider of high-precision biometric identifica...n the company,s core product line: VeriLook 4.0 ...ion and MegaMatcher 3.1 SDK for large-scale mult...on systems (AFIS). Expanded capabilities in VeriLo...
(Date:11/26/2009)...harks are some of the Ocean,s most distinctive res...e this strange head shape, says Michelle McComb f...on is the shark,s vision. ,Perhaps their visual fi...says McComb, giving the sharks excellent stereovis...Comb, there were two schools of thought on this th...
(Date:11/26/2009)...ave at last worked out a way of using recordings o...populations. This is the first time sound recordin...to accurate estimates of bird species, populations...sh Ecological Society,s Journal of Applied Ecolog...to a major advance in our ability to monitor whale...
Breaking Biology News(10 mins):New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 3Wide heads give hammerheads exceptional stereo view 2Ecologists sound out new solution for monitoring cryptic species 2Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases 5908 1Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases 5908 2Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases 5908 3Arcadia Resources Announces Webcast of Its Fiscal 2010 Second Quarter Conference Call 5902 1Arcadia Resources Announces Webcast of Its Fiscal 2010 Second Quarter Conference Call 5902 2Arcadia Resources Announces Webcast of Its Fiscal 2010 Second Quarter Conference Call 5902 3Arcadia Resources Announces Webcast of Its Fiscal 2010 Second Quarter Conference Call 5902 410 Ways to Get the Most out of Your Translation Service 3A Avantpage Reports on Industry Best Practices 60508 110 Ways to Get the Most out of Your Translation Service 3A Avantpage Reports on Industry Best Practices 60508 2
...ENO, Nev. If you couldn,t believe your eyes when ...aking 771-pound stingray, you may have been on to ...ere,s no denying that this is a huge stingray, the...ity of Nevada, Reno conservation biologist Zeb Hog... Project," a joint venture with the National Geogr...
...ientists have discovered how the toxoplasmosis par... and other bipolar disorders. , The team from the...es (UK) has shown that the parasite may play a rol...ng the production of dopamine - the chemical that ...f movement, cognition and behaviour. , Toxoplasmo...
...lymorphisms are variations in genes which can resu...ns and thus may be associated with susceptibility ...al Science , a journal of the Association for Psyc...nd her colleagues from the Karolinska Institutet i...ny examined the effect of specific polymorphisms o...
Other Biology News:Tall tale of giant stingray circles the globe 2Research supports toxoplasmosis link to schizophrenia 2The genetics of fear: Study suggests specific genetic variations contribute to anxiety disorders 2
...s a dedicated imaging system for detection of very... Equipped with an extreme sensitive camera to dete...esearch, infectious disease research, gene express...s the only imager with a motor-driven camera insid...
...s a dedicated imaging system for fluorescent light...sitive camera to detect low level light in animals...esearch, gene expression, circadian rhythm, gels a... a motor-driven camera inside the light-tight cabi...
Mouse Anti-Human COG2 Monoclonal Antibody, Unconjugated, Clone 4C8 from Abnova Corporation
Mouse Anti-Human AGTRAP Polyclonal Antibody, Unconjugated from Abnova Corporation
Biology Products: